Genetic analysis now plays a central role in confirming FH diagnoses and informing clinical management, especially through identification of pathogenic variants in LDLR, APOB, and PCSK9 genes [5, 6]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.